News from debiopharm international sa A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 30, 2019, 12:19 ET GenePOC, a Subsidiary of Debiopharm Group, Reaches an Agreement With Meridian Bioscience for the Acquisition of Their Molecular Diagnostics Business

Debiopharm (www.debiopharm.com), announced today having reached an agreement with Meridian Bioscience, Inc. for Meridian to acquire GenePOC's...


Apr 01, 2019, 08:33 ET Debiopharm Releases Results of 3 Key Oncology Compound Programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA

Debiopharm, (www.debiopharm.com/debiopharm-international/) a global biopharmaceutical company based in Switzerland, today announced data releases on...


Feb 26, 2019, 08:33 ET Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections

Debiopharm International SA (Debiopharm – www.debiopharm.com/debiopharm-international/), part of Debiopharm Group™, a Swiss-based global...


Feb 14, 2019, 08:38 ET Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II Study Evaluating Debio 1347 in Advanced Solid Tumors Harboring an FGFR fusion

Debiopharm International SA (Debiopharm – www.debiopharm.com/debiopharm-international/), part of Debiopharm Group™, a Swiss-based global...


Jan 07, 2019, 10:00 ET Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America

Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a...


Oct 11, 2018, 08:38 ET Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology

Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research...


May 08, 2018, 08:00 ET FDA Grants Fast Track Designation to Debiopharm International's Debio 1347 for the Treatment of Patients With Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration

Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, announced...


May 08, 2018, 03:00 ET La FDA accorde la désignation Fast Track au Debio 1347 de Debiopharm International pour le traitement des patients atteints de tumeurs non résécables ou métastatiques avec une altération du gène FGFR

Debiopharm International SA (Debiopharm - www.debiopharm.com), membre de Debiopharm Group™, une société pharmaceutique basée en Suisse, a annoncé...


Apr 05, 2018, 08:00 ET Kaiku Health Raises €4.4 Million Series A Financing to Accelerate Its Digital Therapeutics Pipeline Led by Debiopharm and Tesi

Finnish digital health company Kaiku Health Oy, which provides intelligent patient monitoring software for healthcare providers across Europe, has...


Apr 05, 2018, 03:20 ET Kaiku Health lève 4,4 millions € pour un financement de série A afin d'accélérer son portefeuille numérique de produits thérapeutiques avec Debiopharm et Tesi

La société finlandaise spécialisée dans le domaine de la santé numérique, Kaiku Health Oy, qui fournit un logiciel intelligent de suivi des patients...


Feb 19, 2018, 08:00 ET GenePOC lance son instrument revogene™ et son test GBS LB au Canada

GenePOC Inc., membre de Debiopharm Group™, est fier d'annoncer le lancement de son test GenePOC™ GBS LB, utilisable avec l'instrument revogene. À...


Feb 19, 2018, 08:00 ET GenePOC Launches Its revogene™ Instrument and GBS LB Test in Canada

GenePOC Inc., member of the Debiopharm Group™, is proud to announce the launch in its home market for the revogene instrument and the GenePOC™ GBS LB ...


Feb 15, 2018, 09:00 ET Debiopharm Continues the Fight Against Antibiotic Resistance With Investment in ABAC Therapeutics Inc.

Debiopharm Group ™ announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This...


Feb 15, 2018, 09:00 ET Debiopharm poursuit le combat contre les résistances aux antibiotiques avec un investissement dans ABAC Therapeutics Inc.

ABAC développe de nouveaux antibiotiques ciblés destinés aux patients souffrant d'infections sévères Debiopharm Group™ annonce un investissement dans ...


Feb 15, 2018, 03:00 ET Debiopharm poursuit le combat contre les résistances aux antibiotiques avec un investissement dans ABAC Therapeutics Inc.

ABAC développe de nouveaux antibiotiques ciblés destinés aux patients souffrant d'infections sévères Debiopharm Group™ annonce un investissement dans ...


Nov 28, 2017, 07:00 ET GenePOC lance son test GenePOC™ CDiff aux Etats-Unis

GenePOC annonce le lancement et l'approbation par la FDA de son test moléculaire Clostridium difficile aux États-Unis. GenePOC Inc. (GenePOC), membre ...


Nov 28, 2017, 07:00 ET GenePOC Launches its GenePOC™ CDiff Test in the United States

GenePOC Inc. (GenePOC), a member of the Debiopharm Group™, is proud to announce the launch of its 2nd FDA cleared assay in less than 6 months,...


Nov 22, 2017, 02:00 ET Lancement de « patients.debiopharm.com », un site internet sur les essais cliniques de Debiopharm International SA

Le site Internet fournit aux patients des renseignements utiles sur les essais cliniques de la société Debiopharm International SA (Debiopharm -...


Nov 22, 2017, 02:00 ET Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com

Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, announced...


Nov 14, 2017, 02:00 ET EMA Grants Orphan Drug Designation to Debiopharm International SA's FGFR Inhibitor Debio 1347 in the Treatment of Biliary Tract Cancer

Debiopharm International SA (Debiopharm - http://www.debiopharm.com), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company,...


Nov 06, 2017, 08:00 ET Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)

Debiopharm International SA (Debiopharm - http://www.debiopharm.com), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company,...


Oct 12, 2017, 09:00 ET GenePOC Launches its new GenePOC™ GBS DS Test

GenePOC announces the launch of its Group B Streptococcus Direct Swab (DS) molecular test in Europe GenePOC, Inc. (GenePOC), a member of the...


Oct 12, 2017, 03:00 ET GenePOC annonce le marquage CE de son nouveau test GenePOC™ GBS DS

GenePOC annonce le lancement de son test moléculaire Streptocoque de groupe B sur écouvillon direct en Europe.[i] GenePOC, Inc. (GenePOC), membre de...


Oct 04, 2017, 13:35 ET Arbor Pharmaceuticals, LLC y Debiopharm International SA anuncian la disponibilidad en el mercado de Triptodur™, formulación de triptorelina 6 meses para tratamiento de la Pubertad Precoz Central (PPC)

Triptodur™, (triptorelina) suspensión inyectable de liberación lenta, ha demostrado detener o anular los signos clínicos de la pubertad asociados con ...


Oct 03, 2017, 08:53 ET Arbor Pharmaceuticals, LLC & Debiopharm International annoncent la commercialisation de Triptodur™, formulation triptoréline 6 mois, pour le traitement des patients atteints de puberté précoce centrale

Il a été démontré que Triptodur™ (triptoréline), suspension injectable à libération prolongée, pouvait enrayer ou inverser l'évolution des signes...